Unlock instant, AI-driven research and patent intelligence for your innovation.

Anti-tumor compounds

A compound and chemical formula technology, applied in the field of anti-tumor compounds, can solve problems such as limiting efficacy in vivo

Inactive Publication Date: 2008-02-27
NAT INST OF HEALTH REPRESENTED BY THE SEC OF THE DEPT OF HEALTH & HUMAN SERVICES NAT INST OF HEALTH +1
View PDF1 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The low water solubility of CA-4 limits its efficacy in vivo

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-tumor compounds
  • Anti-tumor compounds
  • Anti-tumor compounds

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0052] Example 1: (7-methoxy-imidazo[1,2-a]pyridine-3-yl)-(3,4,5-trimethoxy-phenyl)-methanone ((7-methoxy- Synthesis of imidazo[1,2-a]pyridin-3-yl)-(3,4,5-trimethoxy-phenyl)-methanone)(Compound 1)

[0053]According to Luo Bo et al. in "Journal of Bioorganic Medicinal Chemistry" 1999, 9 (1), 97-102 pages (Loeber, S., et al., Bioorg Med Chem Lett 1999, 9 (1), 97-102) 7-Methoxy-imidazo[1,2-a]pyridine (7-Methoxyimidazo[1,2-a]pyridine) was prepared by the method described above.

[0054] Mix 7-methoxy-imidazo[1,2-a]pyridine (621 mg, 4.2 mmol) with POCl in dimethylformamide (4 mL) 3 (16.8 mmol). The reaction mixture was heated at 90 °C for 24 hours and then cooled to room temperature. The solvent was removed in vacuo to give an oil. The oil was purified on a silica gel column eluting with EtOAc / hexanes (1:1) to afford 7-methoxy-imidazo[1,2-a]pyridine-3-carboxylic acid indole (7-methoxyimidazo [1,2-a]pyridine-3-carbaldehyde) (508 mg, 69%).

[0055] Into a dry flask equipped wit...

Embodiment 2

[0058] Example 2: (7-methoxy-2-methyl-imidazo[1,2-a]pyridine-3-yl)-(3,4,5-trimethoxy-phenyl)-methanone ( Compound 2) Synthesis of ((7-methoxy-2-methyl-imidazo[1,2-a]pyridin-3-yl)-(3,4,5-trimethoxy-phenyl)-methanone)

[0059] 4-methoxy-2-aminopyridine (4-methoxy-2-aminopyridine) (1.07 g, 8.6 mmol) in EtOH (50 mL) was mixed with ethyl 2-chloroacetoacetate (5.4 The mixture of g) was refluxed for 24 hours. The reaction mixture was then concentrated to half its volume with CH 2 Cl 2 Extraction, first using brine and then washing with water, passing through anhydrous MgSO 4 dry. The solvent was removed in vacuo and the residue was treated with ethyl acetate (EtOAc) followed by MeOH / CH 2 Cl 2 (1:9) elution for purification to provide 7-methoxy-2-methylimidazo[1,2-a]pyridine-3-carboxylate (7-methoxy-2-methylimidazo[1,2 -a] pyridine-3-carboxylate) (2.71 g, 90%).

[0060] As the product mixture (0.340 g, 1.04 mmol) in THF (15 mL) at 0 °C N 2 Stir on low for 10 minutes. Add lit...

Embodiment 3

[0063] Example 3: (6-methoxy-3a, 7a-dihydro-1H-indazole-3-yl)-(3,4,5-trimethoxy-phenyl)-methanone ((6-methoxy Synthesis of -3a,7a-dihydro-1H-indazol-3-yl)-(3,4,5-trimethoxy-phenyl)-methanone) (compound 3)

[0064] The mixture (0.200g, 1.04mmol) of 6-methoxy-1H-indazole-3-carboxylic acid (6-methoxy-1H-indazole-3-carboxylic acid) in THF (15mL) was at 0 ℃ N 2 Stir for 10 minutes. Add lithium aluminum hydride (LAH), in N 2 The mixture was stirred overnight at room temperature. Then, add NH 4 Cl aqueous solution (5 mL), the reaction mixture was concentrated to half its volume and extracted with ethyl acetate (EtOAc). The organic layer was washed with brine and water, and anhydrous MgSO 4 After drying, the solvent was removed in vacuo to yield a residue. MnO was stirred at 0°C 2 (0.680g, 7.8mmol) was added to anhydrous CH 2 C1 2 (15 mL) of the residue. After the addition, the mixture was stirred at room temperature for 8 hours, and the mixture was diluted with anhydrous di...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
absorbanceaaaaaaaaaa
Login to View More

Abstract

Compounds of formula (I); wherein A, D, Q, T, U, V, W, X, Y, Z, R1, and formula (II) are as defined herein. This invention also relates to a method of inhibiting tubulin polymerization, or treating cancer or an angiogenesis-related disorder with one of these compounds.

Description

Background technique [0001] Cancer treatment can be achieved through a variety of treatment modalities, including surgery, radiation therapy, chemotherapy, or any combination of the above. Among them, chemotherapy is indispensable for inoperable or metastatic cancers. [0002] The microtubule system of eukaryotic cells is an important target for the development of anticancer agents. More specifically, tubulin polymerization / depolymerization is a common target for new chemotherapeutic agents. Various clinically used compounds (e.g. paclitaxel, epothilone A, vinblastine, A-4 phosphate, dolastatin 10, colchicine) target tubulin polymerization / depolymerization, dividing cellular microtubules structure, causing mitotic arrest and inhibiting the generation of new vascular epithelial cells. See Jordan et al. (1998) Med. Res. Rev. 18:259-296. Thus, the above-mentioned compounds can inhibit excessive angiogenesis, which occurs in, for example, cancer (solid tumors and blood tumors)...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D487/00
CPCC07D307/80C07D471/04C07D231/56C07D487/04A61K31/503A61K31/519A61K31/498A61K31/52C07D333/56A61K31/53A61P1/04A61P15/00A61P17/06A61P19/02A61P27/02A61P29/00A61P35/00A61P35/02A61P43/00A61P9/00A61P9/10A61P9/14A61P3/10
Inventor 谢兴邦赵宇生刘景平张俊彦董彦士
Owner NAT INST OF HEALTH REPRESENTED BY THE SEC OF THE DEPT OF HEALTH & HUMAN SERVICES NAT INST OF HEALTH